- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) today announced new data showing that SPL7013, the active ingredient in its topical microbicide VivaGel(R), inhibits all four strains of the human papillomavirus (HPV) targeted by the two marketed cervical cancer vaccines.
These pre-clinical results extend those of a previous study showing that SPL7013 was active against two of the four strains targeted by the vaccines. SPL7013 has now been shown to have in vitro activity against HPV-16 and -18, which account for approximately 70% of cervical cancers; and HPV-6 and -11, which together account for approximately 90% of the incidence of genital warts.
In addition, the latest results demonstrate SPL7013 to be active against HPV-31. Previously SPL7013 has been demonstrated to be active against HPV-45. These two strains have been implicated in more than 4% of cervical cancers but neither is included in the existing vaccines.
Starpharma CEO, Dr Jackie Fairley said: "The new data support our earlier findings that VivaGel(R) may have potential for reducing the risk of genital HPV infection, the most common sexually transmitted infection in the United States."
"Showing that VivaGel(R) has activity against all major clinically relevant strains of HPV tested so far, in particular those strains not covered by the current cervical cancer vaccines, further strengthens the growing body of evidence demonstrating the efficacy of SPL7013 against several important STIs."
In the US, 6.2 million people are newly infected with HPV each year. HPV infection is a factor in the development of virtually all cases of cervical cancer.
VivaGel(R) is currently under clinical development as a vaginal microbicide for the prevention of transmission of HIV and genital herpes (HSV-2).
About Starpharma Holdings Ltd
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
For more information, please click here
Dr Jackie Fairley
Chief Executive Officer
Copyright © Starpharma Holdings LimitedIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information